<DOC>
	<DOCNO>NCT00358072</DOCNO>
	<brief_summary>The study aim optimize concept risk-oriented postremission consolidation therapy , offer ( ) standard consolidation-maintenance patient low risk relapse define MRD ( Minimal Residual Disease ) negative status , ( ii ) allogeneic stem cell transplantation ( related/unrelated donor available ) multicycle high-dose therapy autologous blood stem cell transplant ( donor ) patient high risk relapse define MRD+ status . The prognostic role MRD evaluation unselected patient evaluate .</brief_summary>
	<brief_title>Treatment Adult ALL With MRD-directed Programme .</brief_title>
	<detailed_description>Improved outcome adult ALL application : - Risk-adapted induction ( cycle . 1 : IVAP i.e idarubicin-vincristine-asparaginase-prednisone , plus fractionated cyclophosphamide T-ALL , imatinib Ph/BCR-ABL+ ALL ) - Risk stratification ( clinical ) accord morphology , immunophenotype , cytogentics molecular biology result . Standard risk ( SR ) define pre-B CD10+ phenotype , Ph/BCR-ABL- status , blast count &lt; 10x10e9/L . All subgroup HR ( high-risk ) except Ph/BCR-ABL+ ( 4 ; 11 ) + ALL ( VHR , high-risk ) - Homogeneous early consolidation programme include conventional therapy idarubicin-vincristine-cyclophosphamide-dexamethasone/prednisone ( cycle . 2,3,5,6,8 ) high-dose treatemt MTX/Ara-C ( cycle . 4,7 ) meningeal prophylaxis ( triple intrathecal therapy x8-12 , skull irradiation ) , plus imatinib Ph+ ALL ( Phase A ) . Autologous bllo stem cell mobilize cryopreserved cycle . 4 . - Serial evaluation minimal residual disease ( MRD ) RQ-PCT technology , aim define individual patient rate reduction early consolidation . The molecular study centralize aim obtain one patient-specific probe ( ) sensitivity least 10e-3 . Patient bone marrow sample MRD analysis timepoints 13 i.e . cycle no.3,5 , 7 . Only patient negative result timepoint 3 negative/low positive ( &lt; 10e-4 ) result timepoint 3 consider MRD- , combination regard MRD+ . - Phase B therapy accord MRD result ALL subset : - MRD- nonPh/t ( 4 ; 11 ) : standard maintenance - MRD+ nonPh/t ( 4 ; 11 ) : allogeneic stem cell transplantation ( sibling/MUD ) , alternatively , intensify high-dose therapy ( 2-4 `` hypercycles '' ) autologous stem cell support anti CD20 MoAb ( CD20+ ) , follow maintenance . Each `` hypercycle '' consist high-dose mercaptopurine-etoposide-melphalan ( cycle . 1,3 ) methotrexate-cytarabine ( cycle . 2,4 ) - MRD unknown nonPh/t ( 4 ; 11 ) : treatment clinical risk ( SR : maintenance ; HR , per MRD+ ) - Ph/t ( 4 ; 11 ) + : allogeneic stem cell transplantation soon possible complete remission ; transplant possible , consolidation HR patient . cycle supplement imatinib Ph+ ALL The illustrated strategy aim optimize postremission consolidation therapy offer standard treatment `` '' patient low risk relapse ( MRD- ) , thereby reduce risk high dose treatment ( expect TRM allogeneic SCT 20-30 % ) , maintain latter approach MRD+ case HR subset . The prognostic role MRD evaluation unselected patient evaluate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<criteria>Untreated Acute lymphoblastic leukemia lymphoblastic lymphoma ( Tcell , precursor Bcell ) Age 1565 year ( old patient biologically fit accord responsible physician ) Written informed consent Any comorbidity preclude administration intensive chemotherapy adult ALL</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>Adult patient</keyword>
	<keyword>Minimal residual disease</keyword>
	<keyword>Risk-oriented therapy</keyword>
</DOC>